{
    "pmcid": "11659936",
    "qa_pairs": {
        "How have nanobodies been applied in the context of the COVID-19 pandemic?": [
            "Targeting the SARS-CoV-2 spike protein to prevent viral entry",
            "Developing vaccines against SARS-CoV-2",
            "Enhancing the immune response through adjuvant activity",
            "Blocking the replication of SARS-CoV-2 within host cells"
        ],
        "What evolutionary advantage do camelid heavy-chain antibodies provide according to the paper?": [
            "Simplified antibody structure for effective antigen recognition and neutralization",
            "Increased antibody diversity for broader pathogen recognition",
            "Enhanced ability to cross the blood-brain barrier",
            "Improved interaction with human immune cells"
        ],
        "What is the primary source of nanobodies discussed in the paper?": [
            "Camelid heavy-chain antibodies (HCAbs)",
            "Mouse monoclonal antibodies",
            "Humanized monoclonal antibodies",
            "Recombinant protein libraries"
        ],
        "What methods are mentioned for screening potent monoclonal nanobodies?": [
            "Phage display and yeast display",
            "Flow cytometry and ELISA",
            "Western blotting and immunoprecipitation",
            "Mass spectrometry and chromatography"
        ],
        "Which nanobody-based drugs are highlighted as examples of commercialization in the paper?": [
            "Cablivi and Envafolimab",
            "Remdesivir and Tocilizumab",
            "Dexamethasone and Hydroxychloroquine",
            "Molnupiravir and Paxlovid"
        ]
    }
}